Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986550 | 0.93 | ALDH1A1 (0.39) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL14517952 | 0.84 | CES2 (0.32) | PAOXALDH1A1ACHE | |
| SCHEMBL2988734 | 0.84 | ALDH1A1 (0.43) | PAOXALDH1A1ACHELMNASLC15A2 | |
| SCHEMBL25899667 | 0.83 | ALDH1A1 (0.54) | ALDH1A1LMNATSHR | |
| SCHEMBL11350161 | 0.81 | TSHR (0.56) | ALDH1A1LMNATSHR | |
| SCHEMBL11329622 | 0.81 | FAAH (0.42) | ALDH1A1FAAHTSHR | |
| SCHEMBL29169497 | 0.79 | PPARD (0.52) | PAOXTSHR | |
| SCHEMBL11515947 | 0.78 | FAAH (0.46) | ALDH1A1FAAH | |
| SCHEMBL18393454 | 0.76 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL8184057 | 0.76 | ALDH1A1 (0.50) | ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | PAOX 3404/4885ALDH1A1 4367/4885ACHE 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.